[1]
Ross I. A.: Medicinal Plants of the World. Chemical constituents,
traditional and modern medicinal uses. Humana Press, Totowa, New
Jersey 2005, s. 29–116.
[2]
Cartwright A. C.: The British Pharmacopoeia 1864-2014 Medicines,
International Standards and the State. Ashgate Publishing Limited,
Dorset 2015, s. 171.
[3]
Robson P. J.: Therapeutic potential of cannabinoid medicines. Drug Test
Anal 2014; 6: 24–30.
[4]
Mechoulam R. Plant cannabinoids: a neglected pharmacological treasure
trove. Br J Pharmacol 2005; 146: 913–915.
[5]
Gaoni Y., Mechoulam R.: Isolation, structure, and partial synthesis of an
active constituent of hashish. J Am Chem Soc 1964; 86: 1646–1647.
[6]
Devane W. A., Dysarz F. A., Johnson M. R., et al.: Determination and
characterization of a cannabinoid receptor in rat brain. Mol Pharmacol
1988; 34: 605–613.
[7]
Matsuda L. A., Lolait S. J., Browstein M. J.: Structure of a cannabinoid
receptor and functional expression of the cloned cDNA. Nature 1990;
346: 561–564.
[8]
Munro S., Thomas K. L., Abu-Shaar M.: Molecular characterization of a
peripheral receptor for cannabinoids. Nature 1993; 365: 61–65.
[9]
Kwolek G., Zakrzewska A., Kozłowska H., et al.: Wpływ anandamidu,
endogennego agonisty receptorów kannabinoidowych na układ krążenia.
Postępy Hig Med Dośw 2005; 59: 208–218.
[10]
Leite C. E., Mocelin C. A., Petersen G. O.: Rimonabant: an antagonist drug
of the endocannabinoid system for the treatment of obesity. Pharmacol
Rep 2009; 61: 217–224.
[11]
Pawłowski M., Westphal Ł., Wesołowska A.: Rimonabant – pierwszy
antagonista receptora kanabinoidowego CB1. Czasopismo Aptekarskie
2009; 12: 24–30.
[12]
Lamer-Zarawska E., Kowal-Gierczak B., Niedworok J.: Fitoterapia i leki
roślinne. PZWL, Warszawa 2012, s. 500.
[13]
Kędzia A., Ziółkowska-Klinkosz M., Kochańska B., et al.: Ocena
aktywności olejku eterycznego z Cannabis sativa L. wobec bakterii
beztlenowych. Postępy Fitoterapii 2014; 3: 136–140.
[14]
Casanova M. L., Blázquez C., Martínez-Palacio J., et al.: Inhibition of skin
tumor growth and angiogenesis in vivo by activation of cannabinoid
receptors. J Clin Invest 2003; 1: 43–50.
[15]
Seńczuk W.: Toksykologia współczesna. Wydawnictwo Lekarskie
PZWL, Warszawa 2006, s. 323–325.
[16]
Formukong E. A., Evans A. T., Evans F. J.: Inhibition of the cataleptic
effect of tetrahydrocannabinol by other constituents of Cannabis sativa
L. J Pharm Pharmacol 1988; 40: 132–134.
[17]
Appendino G., Gibbons S., Giana A.: Antibacterial cannabinoids from
Cannabis sativa: a structure-activity study. J Nat Prod 2008; 71: 1427–
1430.
[18]
Gorzalka B. B., Hill M. N.: Putative role of endocannabinoid signaling
in the etiology of depression and actions of antidepressants. Prog
Neuropsychopharmacol Biol Psychiatry 2011; 35: 1575–1585.
[19]
Morgan C. J., Curran H. V.: Effects of cannabidiol on schizophrenia-like
symptoms in people who use cannabis. Br J Psychiatry 2008; 192:
306–307.
[20]
Morgan C. J., et all. Cannabidiol reduces cigarette consumption in
tabacco smokers: preliminary findings. Addict Behav 2001; 38: 2433–
2436.
[21]
Pietrzak B., Dunaj A., Piątkowska K.: Rola układu kannabinoidowego
w patogenezie oraz poszukiwaniu nowych możliwości farmakoterapii
zespołu zależności alkoholowej. Postępy Hig Med Dośw 2011; 65: 606–
615.
[22]
Szaflarski J. P., Bebin E. M.: Cannabis, cannabidiol and epilepsy – from
receptors to clinical response. Epilepsy & Behavior 2014, 41: 277–282.
[23]
Porter B. E., Jacobson C.: Report of parent survey of cannabidiolenriched
cannabis use in pediatric treatment-resistant epilepsy. Epilepsy
Behav. 2013; 29: 574–577.
[24]
Porter B. E., Jacobson C.: Seizing an opportunity for the endocannabinoid
system. Epilepsy Curr 2014; 14: 272–276.
[25]
Hussain S. A., Zhou R., Jacobson C., et al.: Perceived efficacy of
cannabidiol-enriches cannabis extracts for treatment of pediatric
epilepsy: A potential role for infantile spasms and Lennox-Gastaut
sundrome. Epilepsy Behav 2015; 47: 138–141.
[26]
Valdeolivas S., Navarrete C., Cantarero I., et al.: Neuroprotective properties
of cannabigerol in Huntington’s disease: studies in R6/2 mice and
3-nitropropionate-lesioned mice. Neurotherapeutics 2015; 12: 185–199.
[27]
Borelli F., Fasolino I., Romano B.: Beneficial effect of the non-psychotropic
plant cannabinoid cannabigerol on experimental inflammatory bowel
disease. Biochem Pharmacol 2013; 85: 1306–1316.
[28]
Colasanti B. K., Craig C. R., Allara R. D.: Intraocular pressure, ocular
toxicity and neurotoxicity after administration of cannabinol or
cannabigerol. Exp Eye Res 1984; 39: 251–259.
[29]
Oomah B. D., Busson M., Godfrey D. V., et al.: Characteristics of hemp
(Cannabis sativa L.) seed oil. Food Chemistry 2002; 76: 33–43.
[30]
Frohne D.: Leksykon roślin leczniczych. Med Pharm Polska, Wrocław
2010, s. 116–118.
[31]
Wyk B.-E., Wink M.: Rośliny lecznicze świata. Med Pharm Polska,
Wrocław 2008, s. 77.
[32]
Benbadis S. R., Zesiewicz T. A., Sanches-Ramos J., et al.: Medical
marijuana in neurology. Exper Rev Neurother 2014; 14: 1453–1465.
[33]
Benbadis S. R., Sanchez-Ramos J., Bozorg A., et al.: Medical marijuana
in neurology. Epilepsy Behav 2013; 29: 574–577.
[34]
Basu S., Dittel B. N.: Unravelling the complexities of cannabinoid
receptor 2 (CB2) immune regulation in health and disease. Immunol Rev
2011; 51: 26–38.
[35]
Cohen S. P.: Cannabinoids for chronic pain. BMJ 2008; 336: 167–168.
[36]
Pertwee R. G.: Cannabinoid pharmacology: the first 66 years. Br J
Pharmacol 2006; 147: 163–171.
[37]
Agar E.: The role of cannabinoids and leptin in neurological diseases.
Acta Neurol Scand 2015; 132: 371–380.
[38]
Zimmer A., Zimmer A. M., Hohmann A. G., et al.: Increased mortality,
hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout
mice. Proc Natl Acad Sci USA 1999; 96: 5780–5785.
[39]
Alger B. E.: Seizing an Opportunity for the Endocannabinoid System.
Epilepsy Curr 2014; 14: 272–276.
[40]
Cravatt B. F.: The endogenous cannabinoid system and its role in
nociceptive behavoir. Inc J Neurobiol 2001; 61: 149–160.
[41]
Ronan P. J., Wongngamnit N., Beresford T. P.: Molecular mechanisms
of cannabis signaling in the brain. Prog Mol Biol Transl Sci 2016; 137:
123–147.
[42]
Tasker J. G., Chen C., Fisher M. O., et al.: Endocannabinoid regulation of
neuroendocrine systems. Rev Neurobiol 2015 2015; 125: 163–201.
[43]
Giuffrida A., Beltramo M., Piomelli D.: Mechanisms of endocannabinoid
inactivation: biochemistry and pharmacology. JPET 2001; 298: 7–14.
[44]
van der Stelt M., Di Marzo V.: Cannabinoid receptors and their role in
neuroprotection. Neuromolecular Med 2005; 7: 37–50.
[45]
Piomelli D.: The molecular logic of endocannabinoid signalling. Nat Rev
Neurosci 2003; 4: 873–884.
[46]
Katona J.: Cannabis and endocannabinoid signalling in epilepsy. Handb
Exp Pharmacol 2015; 231: 285–316.
[47]
Fernández-Ruiz J., Romero J., Ramos J. A.: Endocannabinoids and
neurodegenerative disorders: Parkinson’s Disease, Huntington’s Chorea,
Alzheimer’s Disease, and others. Handb Exp Pharmacol 2015; 231: 233–
59.
[48]
Jones N. A., Hill A. J., Smith I., et al.: Cannabidiol displays antiepileptiform
and antiseizure properties in vitro and in vivo. JPET 201; 332: 569–577.
[49]
Blair R. E., Deshpande L. S., De Lorenzo R. J.: Cannabinoids: is there a
potential treatment role in epilepsy? Expert Opin Pharmacother 2015; 16:
1911–1914.
[50]
Lendulka O., Dovrtelova G., Naskova K., et al.: Cannabinoids and
cytochrome P450. Curr Drug Metab 2016; 17: 206–226.
[51]
Camfield P., Camfield C.:. Incidence, prevalence and aetiology of seizures
and epilepsy in children. Epileptic Disord 2015; 17: 117–123.
[52]
Maa E., Figi P.: The case for medical marijuana in epilepsy. Epilepsia
2014; 55: 783–786.
[53]
Filloux F. M.: Cannabinoids for pediatric epilepsy? up in smoke or real
science? Transl Pediatr 2015; 4: 271–282.
[54]
Devinsky O., Cilio M. R., Cross H., et al.: Cannabidiol: Pharmacology
and potential therapeutic role in epilepsy and other neuropsychiatric
disorders. Epilepsia 2014; 55: 791–802.
[55]
Rosenberg E. C., Tsien R. W., Whalley B. J., et al.: Cannabinoids and
epilepsy. Neurotherapeutics 2015; 12: 747–768.
[56]
Mathern G., Nehlig A., Sperling M.: Cannabidiol and medical marijuana
for the treatment of epilepsy. Epilepsia 2014; 55: 781–782.
[57]
Dos Santos R. G., Hallak J. E. C., Leite J. P., et al.: Phytocannabinoids and
epilepsy. JCPT 2015; 40: 135–143.
[58]
Gloss D., Vickrey B.: Cannabinoids for epilepsy. Cochrane Database Syst
Rev. 2014 Mar 5; 3: CD009270.
[59]
Mechoulam R., Carlini E .A.: Toward drugs derived from cannabis.
Naturwissenschaften 1978; 65: 174–179.
[60]
Cunha J. M., Carlini E. A., Pereira A. E., et al.: Chronic administration of
cannabidiol to healthy volunteers and epileptic patients. Pharmacology
1980; 21: 175–185.
[61]
Ames F. R., Cridland S.: Anticonvulsant effect of cannabidiol. South
African Medical Journal 1985; 69: 14.
[62]
Trembly B., Sherman M.: Double-blind clinical study of cannabidiol as
a secondary anticonvulsant. Marijuana ’90 International Conference
on Cannabis and Cannabinoids; 1990 July 8–11; Kolympari, Crete.
International Association for Cannabinoid Medicines, 1990: section 2, s.
5.
[63]
GW Pharmaceuticals provides update on orphan program in childhood
epilepsy for Epidiolex [dostęp 2014-06-11].
[64]
GW Pharmaceuticals receives orphan drug designation by FDA for
Epidiolex® in the treatment of Lennox-Gastaut syndrome [dostęp 2014-
06-11].
[65]
Geffrey A. L., Pollack S. F., Bruno P. L., et al.: Drug-drug interaction
between clobazam and cannabidiol in children with refractory epilepsy.
Epilepsia 2015; 56: 1246–1251.
[66]
Friedman D., Devinsky O.: Cannabinoids in the Treatment of Epilepsy. N
Engl J Med 2015; 373: 1048–1058.
[67]
Koppel B. S., Brust J. C., Fife T., et al.: Systematic review: efficacy and
safety of medical marijuana in selected neurologic disorders: report of
the Guideline Development Subcommittee of the American Academy of
Neurology. Neurology 2014; 82: 1556–1563.